BridgeMD
New treatment option for Advanced Solid Tumor
Official title Study of SGR-3515 In Participants With Advanced Solid Tumors.
ClinicalTrials.gov ID: NCT06463340
What this study is testing
What is SGR-3515?
SGR-3515 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of advanced/metastatic solid tumor
- Measurable disease per RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments/procedures
- Adequate bone marrow and organ function
You likely can't join if
- Participants with primary Central Nervous System (CNS tumors).
- Participant has received prior systemic anti-cancer treatments or other investigational agents ≤ 21 days of first dose of study drug, or 5...
- Participant who has received definitive local control radiation (any dose greater than 50 Gy) \< 42 days prior to the first dose of study drug.
- Participant who has received major surgeries ≤ 21 days prior to first dose of study drug
- Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer...
- Participant who has another clinically significant invasive malignancy, as determined by the investigator, ≤ 2 years prior to the first dose
See the full eligibility criteria
- Diagnosis of advanced/metastatic solid tumor
- Measurable disease per RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments/procedures
- Adequate bone marrow and organ function
- Women of child-bearing potential (WOCBP) or males must agree to use highly effective contraception for the duration of study and for 90 days after the last dose of study drug
- Participants with primary Central Nervous System (CNS tumors).
- Participant has received prior systemic anti-cancer treatments or other investigational agents ≤ 21 days of first dose of study drug, or 5 half-lives, whichever is shorter
- Participant who has received definitive local control radiation (any dose greater than 50 Gy) \< 42 days prior to the first dose of study drug.
- Participant who has received major surgeries ≤ 21 days prior to first dose of study drug
- Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade 2 alopecia, peripheral neuropathy and ototoxicity.
- Participant who has another clinically significant invasive malignancy, as determined by the investigator, ≤ 2 years prior to the first dose
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
- Chicago, Illinois, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- New York, New York, United States
- Charlotte, North Carolina, United States
- Cincinnati, Ohio, United States
- Columbus, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Fairfax, Virginia, United States
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States; Chicago, Illinois, United States; Ann Arbor, Michigan, United States; Detroit, Michigan, United States; New York, New York, United States; Charlotte, North Carolina, United States and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.